Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients

  • Authors:
    • Kazuki Ohashi
    • Toru Ishikawa
    • Mitsuyuki Suzuki
    • Hiroko Abe
    • Fujiko Koyama
    • Tomomi Nakano
    • Aya Ueki
    • Hirohito Noguchi
    • Erina Hasegawa
    • Shiori Hirosawa
    • Miki Kobayashi
    • Hiroshi Hirosawa
    • Kaede Sato
    • Takako Fukazawa
    • Yuka Maruyama
    • Toshiaki Yoshida
  • View Affiliations

  • Published online on: November 10, 2017     https://doi.org/10.3892/etm.2017.5488
  • Pages:970-976
Metrics: HTML 0 views | PDF 0 views
0

Abstract

Interferon‑free direct acting antiviral agent regimens for chronic hepatitis C (CHC) have been developed. These regimens have shown a high rate of sustained virologic response (SVR), and a reduction in side effects during treatment is also anticipated. However, the impact of the regimens on health‑related quality of life (HRQOL) and side effects during treatment is not fully understood. The purpose of the present study was to evaluate HRQOL in the clinical course of patients with CHC receiving daclatasvir/asunaprevir (DCV/ASV) therapy using the Short Form‑36 (SF‑36) method. Twenty‑eight patients with CHC receiving DCV/ASV therapy were analyzed in the present study, and HRQOL was measured by SF‑36. Patients were asked to fill out the SF‑36 prior to therapy (baseline), following 12 weeks of therapy, at the end of treatment and at SVR week 24 (SVR24) to evaluate HRQOL. Laboratory data were also investigated during the same period, and associations between these results and SF‑36 were investigated. Aspartate aminotransferase, alanine aminotransferase, serum albumin, α‑fetoprotein, platelet counts and Fibrosis (Fib)‑4 index were all significantly improved at each time point when compared with baseline. With regard to alterations in HRQOL during therapy, the ≥70‑year‑old group displayed a significantly greater improvement in physical functioning during the period between baseline and 12 weeks when compared with the <70‑year‑old group. In the analysis of the SF‑36 differences within each group, general health improved significantly in the ≥70‑year‑old group, as well as albumin levels. In addition, Fib‑4‑index significantly improved at all time points (12 and 24 weeks, and SVR24) when compared with baseline in the ≥70‑year‑old group. Therefore, DCV/ASV therapy may improve HRQOL and hepatic functional reserve, particularly in elderly patients.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

2016 Impact Factor: 1.261
Ranked #50/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ohashi, K., Ishikawa, T., Suzuki, M., Abe, H., Koyama, F., Nakano, T. ... Yoshida, T. (2018). Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients. Experimental and Therapeutic Medicine, 15, 970-976. https://doi.org/10.3892/etm.2017.5488
MLA
Ohashi, K., Ishikawa, T., Suzuki, M., Abe, H., Koyama, F., Nakano, T., Ueki, A., Noguchi, H., Hasegawa, E., Hirosawa, S., Kobayashi, M., Hirosawa, H., Sato, K., Fukazawa, T., Maruyama, Y., Yoshida, T."Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients". Experimental and Therapeutic Medicine 15.1 (2018): 970-976.
Chicago
Ohashi, K., Ishikawa, T., Suzuki, M., Abe, H., Koyama, F., Nakano, T., Ueki, A., Noguchi, H., Hasegawa, E., Hirosawa, S., Kobayashi, M., Hirosawa, H., Sato, K., Fukazawa, T., Maruyama, Y., Yoshida, T."Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients". Experimental and Therapeutic Medicine 15, no. 1 (2018): 970-976. https://doi.org/10.3892/etm.2017.5488